STOCK TITAN

Quanterix (QTRX) Stock News

QTRX Nasdaq

Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.

Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.

QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.

Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) announced a Phase 2 contract with the National Institutes of Health, valued at $18.2 million, to advance a novel SARS-CoV-2 antigen test utilizing their Simoa technology. This funding supports clinical validation and aims for emergency use authorization submissions with the FDA. The contract also facilitates expanded manufacturing capacities at Quanterix's Billerica, Massachusetts facility. Initial feasibility of the test was previously supported by a Phase 1 award. The contract period extends through September 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
covid-19
-
Rhea-AI Summary

Quanterix Corporation (NASDAQ: QTRX) has entered a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), granting Abbott access to Quanterix's bead-based technology patents for in vitro diagnostic (IVD) applications. This agreement includes an initial license fee, milestone fees contingent on Abbott's future development achievements, and royalties on sales of licensed products. Quanterix aims to advance precision health through its digital health solution, Simoa, improving disease detection and treatment methods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
none

FAQ

What is the current stock price of Quanterix (QTRX)?

The current stock price of Quanterix (QTRX) is $3.1 as of June 12, 2026.

What is the market cap of Quanterix (QTRX)?

The market cap of Quanterix (QTRX) is approximately 142.7M.